FDA Reshapes Drug Testing Approach - Takeaway - MDSpire
FDA & Government News

FDA Reshapes Drug Testing Approach

The agency outlined early regulatory actions supporting nonanimal methods, including draft guidance, artificial intelligence tools, and expanded use of human-relevant data models.

Share

  • 1

    FDA aims to reduce animal testing by

  • 2

    New alternative methods are being used for drug safety.

  • 3

    AI tools for drug development have been qualified.

  • 4

    More than 90% of drugs safe in animals fail in humans.

  • 5

    New guidance targets nonhuman primate testing.

  • 6

    Collaboration with NIH enhances methodology development.

  • 7

    Alternatives could lower drug costs for patients.

Original Source(s)

FDA Reshapes Drug Testing Approach

  • by Kathryn Wighton

  • April 20, 2026

Related Content

The Tenure Clock Doesn’t Pause for Politics

Academic institutions need a structured response to federal research defunding

The Secrets of the Gut

Going beyond the gut: why microbiome testing is the next big thing in drug development

  • April 20, 2026

  • 6 min
ACP Updates Breast Cancer Screening Guidance

Biennial mammography recommended for ages 50 to 74 years, with shared decision-making outside that range.